ArticleInternational journal of clinical and experimental pathology2025
Biglycan promotes proliferation and metastasis of ovarian cancer.
Article in International journal of clinical and experimental pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic influence of small leucine-rich proteoglycans on serous ovarian cancer.Journal of cancer research and clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOvarian cancer (OC) is a significant threat to the health of women. Biglycan (BGN) plays a crucial role in the oncogenesis and progression of various human cancers. The aim of this study was to clarify the role of BGN in OC.
methodsImmunohistochemical analysis was performed to detect BGN levels in the OC tissues of 68 patients who underwent cytoreductive surgery. Normal ovarian tissues were collected from 21 patients with benign gynecological tumors who underwent oophorectomy. Western blot analysis was conducted to detect BGN levels in human OC and normal ovarian cells. The functions of BGN in OC cells were assessed with the Cell Counting Kit-8, wound healing, and transwell migration assays following upregulation or downregulation of BGN
resultsBGN expression was elevated in OC tissues as compared to normal tissues. The basal level of BGN was also higher in OC cells than in normal cells. Knockdown of BGN reduced the proportion of surviving OC cells, increased wound healing, and decreased cell migration, while overexpression produced the opposite effects.
conclusionsThese findings suggest that high BGN expression enhances proliferation and migration of OC cells, indicating that BGN is a potential target for treatment of OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.